Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Merck is making a major investment into Bothwell, Washington-based Seattle Genetics with two strategic oncology deals.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Orasis Pharmaceuticals has closed on $30 million dollars in Series C financing that will propel its corrective eye drop candidate for presbyopia symptoms, CSF-1, through Phase III clinical trials.
Six months into a global pandemic and public trust is waning in its support for public health officials in charge of the nation’s response to the novel coronavirus, according to a new poll.
The financing will be used by MiNA to advance the company’s pipeline of proprietary, first-in-class, small activating RNA therapeutics.
Despite a temporary pause on its COVID-19 vaccine trial, AstraZeneca Chief Executive Officer Pascal Soriot said the preventative drug could still be available for commercial use by the end of the year, or in early 2021 barring any other setback.
Elizabeth Holmes, the founder and former chief executive officer of failed diagnostics company Theranos, will be examined by a psychologist and psychiatrist ahead of her looming trial for fraud.
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
Earlier this year, BioSpace tallied up the hottest U.S. biotech start-ups in their NextGen Bio Class of 2020 – Anthos Therapeutics was ranked #2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.